Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of Stealth’s elamipretide for the ultra-rare ...

XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics ...

Plaque psoriasis is a chronic condition that affects millions yet is often misunderstood or underappreciated in terms of its ...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...

At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

At CPHI Europe, an expert discussed the promise of gummies as a drug delivery system and their unique manufacturing ...

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Patient recruitment is a critical yet challenging phase in clinical trials. EMIS has been lauded for its significant ...